Priyatham Mettu, MD
Ophthalmology · Durham, NCNPI 1508023284
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $103,450 of the $111,219 with a category attached, or 93.0%. Astellas Pharma Global Development accounts for 84.8% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $50,700, more than ten times the $236 reported in 2019. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $2180.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$94K
- Merck$7K
- Alimera Sciences, Inc.$5K
- Genentech USA, Inc.$2K
- Notal Vision, Inc.$454
- Vertex$325
- plus $1K from 8 others
Across 1 payment — averaging $4100.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$4K
What the payments were for
- Consulting fees$103,45093%
- Speaking & faculty fees$5,0755%
- Travel & lodging$6221%
- Food & beverage$2,0722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 21 | $94,300 |
| Merck | 7 | $7,483 |
| Alimera Sciences, Inc. | 5 | $5,377 |
| Genentech USA, Inc. | 1 | $2,115 |
| Notal Vision, Inc. | 3 | $454 |
| Vertex | 1 | $325 |
| Genentech, Inc. | 4 | $316 |
| Regeneron | 2 | $233 |
| Apellis Pharmaceuticals, Inc. | 2 | $190 |
| Regeneron Healthcare Solutions, Inc. | 1 | $111 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $105 |
| Ocular Therapeutix, Inc. | 1 | $93 |
| Eyepoint US, Inc. | 1 | $82 |
| Bausch & Lomb Americas Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$94,300
- Iluvien$5,289
- VABYSMO$2,251
- EYLEA$220
- ForeseeHome$128
- EYLEA HD$124
- LOTEMAX SM$105
How this compares
$111,219 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 29 | $1,616 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 44 | $1,002 |
| Ketorolac Tromethamine | 41 | $760 |
| Latanoprost | 79 | $650 |
| Brimonidine Tartrate | 27 | $294 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Durham
- Julie WoodwardDurham$1M
- Lejla VajzovicDurham$681K
- Terry KimDurham$605K
- Leon HerndonDurham$230K
- Glenn JaffeDurham$218K
- Robin VannDurham$213K
- Anthony KuoDurham$186K
- Michael RichardDurham$113K
- Jason LissDurham$69K
- Majda HadziahmetovicDurham$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.